Safety and efficacy of nab-paclitaxel (nab-P)-based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2. Article
Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.9058
Web of Science: 000411932202118
Industry Collaboration